Source: Eur Respir J 2009; 34: 1148-1158
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Vardakas K. Z., Matthaiou D. K., Falagas M. E.. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 2009; 34: 1148-1158

Member's Comments

No comment yet.

Related content which might interest you: Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 What is MRSA? Source: Eur Respir J 2009; 34: 1190-1196 Year: 2009 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Clinical outcomes of patients with hospital-acquired pneumonia due to community-associated methicillin resistant staphylococcus aureus (CA-MRSA) Source: Eur Respir J 2007; 30: Suppl. 51, 407s Year: 2007 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Source: Eur Respir J 2004; 24 : 779-785 Year: 2004 The effect of macrolide-resistance on the outcome of patients hospitalized for streptococcus pneumoniae pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Streptococcus pneumoniae resistance pattern and its clinical implications Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Risk factors for methicillin-resistant Staphylococcus aureus isolation from serially obtained sputum in patients hospitalized with pneumonia Source: Virtual Congress 2020 – Clinical challenges in pneumonia Year: 2020 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009 Community-acquired pneumonia due to streptococcus pneumoniae in hospitalized patients – mortality predictors Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Community-acquired pneumonia (CAP) caused by mycoplasma pneumoniae or chlamydophila pneumoniae in children: Are there reliable signs/symptoms for clinical diagnostics? Source: Annual Congress 2013 –The burden of respiratory infections in children Year: 2013 Prevalence and impact on FEV1 decline of methicillin-resistant Staphylococcus aureus infection in patients with cystic fibrosis Source: Annual Congress 2011 - Cystic fibrosis: new basic, clinical and bacteriological knowledge Year: 2011 Methicillin-resistant staphylococcus aureus: The most prevalent cause of ventilator associated pneumonia in Tehran hospitals Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014 Peculiarities of community-acquired pneumonia course, caused by multiresistant strains of S. pneumoniae Source: Eur Respir J 2006; 28: Suppl. 50, 165s Year: 2006 Streptococcus pneumoniae infection is an independent cause of cardiac rhythm alteration in community-acquired pneumonia Source: International Congress 2015 – Prognostic factors in pneumonia: from clinical observations to experimental models Year: 2015 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004